# US 2021/0079074 A1 · Anti-ms4a4a antibodies and methods of use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0079074 A1
- Document ID: US20210079074A1
- Status: Published application
- Kind: A1
- Application number: 16/943,123
- Filed: 2020-07-30
- Published: 2021-03-18
- Earliest claimed: 2019-07-31
- Assignees: Alector LLC
- Applicants: Alector LLC
- Inventors: Jeonghoon SUN; Wei-Hsien HO; Muhammad A. ALHAWAGRI; Philip Ling KONG; Herve RHINN; Hua LONG; Karpagam SRINIVASAN; Ananya MITRA; Daniel P. BERMINGHAM; Klaus-Dieter HEGER; Santiago Viveros SALAZAR; Francesca CIGNARELLA; Ilaria TASSI; Tina SCHWABE; Angie Grace YEE; Arnon ROSENTHAL
- Web page: https://patentgrep.com/patent/US20210079074A1

## CPC

- C07K 16/18: against material from animals or humans
- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61K 2039/505: {comprising antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/31: multispecific
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- C07K 2317/734: Complement-dependent cytotoxicity [CDC]
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal antibodies, humanized antibodies and antibody fragments, that specifically bind a MS4A4A polypeptide, e.g., a mammalian MS4A4A or human MS4A4A, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

## Claims

### Claim 1

An isolated antibody that binds to a MS4A4A protein, wherein the antibody comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises: an HVR-H1 comprising an amino acid sequence selected from the groups consisting of SEQ ID NOs:94, 108, 116, 146, 147, 308, and 311; an HVR-H2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs:96, 97, 98, 99, 110, 111, 118, 119, 120, 121, 122, 149, 150, 151, 152, 153, 309, and 312; and an HVR-H3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs:102, 100, 101, 102, 112, 123, 124, 125, 126, 127, 128, 129, 154, 310, and 313; and the light chain variable region comprises: an HVR-Li comprising an amino acid sequence selected from the group consisting of SEQ ID NOs:104, 103, 113, 130, 131, 132, 133, 134, 135, 136, 137, 138, 156, 157, 158, 314, and 317; an HVR-L2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs:105, 106, 114, 139, 140, 141, 142, 143, 159, 160, 161, 315, and 318; and an HVR-L3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs:107, 115, 144, 145, 163, 316, and 319.

### Claim at position 2

2-6. (canceled)

### Claim 7 (depends on 1)

The antibody of claim 1, wherein the antibody comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises: an HVR-H1 comprising the amino acid sequence of SEQ ID NO:308; an HVR-H2 comprising the amino acid sequence of SEQ ID NO:309; and an HVR-H3 comprising the amino acid sequence of SEQ ID NO:310; and the light chain variable region comprises: an HVR-L1 comprising the amino acid sequence of SEQ ID NO:314; an HVR-L2 comprising the amino acid sequence of SEQ ID NO:315; and an HVR-L3 comprising the amino acid sequence of SEQ ID NO:316.

### Claim at position 4

8-10. (canceled)

### Claim 11

An antibody that binds to a MS4A4A protein, wherein the antibody comprises a heavy chain variable region comprising an HVR-H1, HVR-H2, and HVR-H3 and a light chain variable region comprising an HVR-L1, HVR-L2, and HVR-L3, wherein the antibody comprises the HVR-H1, HVR-H2, HVR-H3, HVR-L1, HVR-L2, and HVR-L3 of antibody 4A-301, 4A-302, 4A-303, 4A-304, 4A-305, 4A-306, 4A-307, 4A-308, 4A-309, 4A-310, 4A-311, 4A-312, 4A-313, 4A-314, 4A-419, 4A-450, 4A-315, 4A-316, 4A-317, 4A-318, 4A-319, 4A-320, 4A-321, 4A-322, 4A-323, 4A-324, 4A-325, 4A-326, 4A-327, 4A-328, 4A-329, 4A-330, 4A-331, 4A-332, 4A-333, 4A-334, 4A-335, 4A-336, 4A-337, 4A-338, 4A-339, 4A-340, 4A-341, 4A-342, 4A-343, 4A-344, 4A-345, 4A-346, 4A-347, 4A-348, 4A-349, 4A-350, 4A-351, 4A-352, 4A-353, 4A-354, 4A-355, 4A-356, 4A-357, 4A-358, 4A-359, 4A-360, 4A-361, 4A-362, 4A-363, 4A-364, 4A-365, 4A-366, 4A-367, 4A-368, 4A-369, 4A-370, 4A-371, 4A-372, 4A-373, 4A-374, 4A-375, 4A-376, 4A-377, 4A-378, 4A-379, 4A-380, 4A-381, 4A-382, 4A-383, 4A-384, 4A-385, 4A-386, 4A-387, 4A-388, 4A-389, or 4A-390.

### Claim at position 6

12-20. (canceled)

### Claim 21 (depends on 1)

The antibody of claim 1, wherein the antibody comprises a heavy chain variable region, wherein the heavy chain variable region comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 5-15, 24-30, 40-53, 76-84 304, and 306.

### Claim at position 8

22-24. (canceled)

### Claim 25 (depends on 1)

The antibody of claim 1, wherein the antibody comprises a light chain variable region, wherein the light chain variable region comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 17-22, 32-36, 55-74, 86-93, 305, and 307.

### Claim at position 10

26-28. (canceled)

### Claim 29 (depends on 1)

The antibody of claim 1, wherein the antibody comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 5-15, 24-30, 40-53, 76-84, 304, and 306, and the light chain variable region comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 17-22, 32-36, 55-74, 86-93 305, and 307.

### Claim at position 12

30-37. (canceled)

### Claim 38 (depends on 1)

The antibody of claim 1 wherein the antibody comprises a heavy chain and a light chain wherein the heavy chain comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 320-327 and the light chain comprises an amino acid sequence of SEQ ID NO:363.

### Claim at position 14

39-40. (canceled)

### Claim 41 (depends on 7)

The antibody of claim 7, wherein the antibody comprises:
a. a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO:304, and the light chain variable region comprises the amino acid sequence of SEQ ID NO:305; or
b. a heavy chain and a light chain wherein the heavy chain comprises the amino acid sequence of SEQ ID NO: 324 or 325, and the light chain comprises the amino acid sequence of SEQ ID NO:363.

### Claim 42

(canceled)

### Claim 43 (depends on 1)

An isolated antibody that binds to a MS4A4A protein, wherein the antibody competitively inhibits binding with the antibody of claim 1 for binding to MS4A4A or binds essentially the same or an overlapping epitope on MS4A4A as the antibody of claim 1.

### Claim at position 18

44-49. (canceled)

### Claim 50 (depends on 1)

The antibody of claim 1, wherein the antibody is human or humanized.

### Claim 51 (depends on 1)

The antibody of claim 1, wherein the antibody (a) decreases cell surface levels of MS4A4A or decreases intracellular levels of MS4A4A, (b) increases soluble TREM2 levels, increases membrane TREM2 levels, or increases soluble TREM2 and increases membrane TREM2 levels in myeloid cells, (c) reduces expression of M2 cell surface markers on myeloid cells and/or (d) increases mRNA and/or protein expression of gelsolin and/or osteopontin on myeloid cells.

### Claim at position 21

52-55. (canceled)

### Claim 56

An isolated antibody that binds to a MS4A4A protein, wherein the antibody increases mRNA and/or protein expression of gelsolin and/or osteopontin on myeloid cells.

### Claim at position 23

57-64. (canceled)

### Claim 65 (depends on 1)

The antibody of claim 1, wherein the antibody is a monoclonal antibody.

### Claim 66

(canceled)

### Claim 67 (depends on 1)

The antibody of claim 1, wherein the antibody further binds to cynomolgus monkey MS4A4A of SEQ ID NO:3

### Claim 68 (depends on 1)

The antibody of claim 1, wherein the antibody is of the IgG class and has an IgG1, IgG2, or IgG4 isotype.

### Claim 69

(canceled)

### Claim 70 (depends on 68)

The antibody of claim 68, wherein the antibody has an IgG 1 isotype and comprises a modified Fc comprising the N325S and L328F mutations according to EU numbering.

### Claim 71 (depends on 1)

The antibody of claim 1, wherein the antibody is an antibody fragment.

### Claim 72 (depends on 71)

The antibody of claim 71, wherein the antibody fragment is a Fab, Fab′, Fab′-SH, F(ab′)2, Fv or scFv fragment.

### Claim 73 (depends on 1)

The antibody of claim 1, wherein the antibody is a bispecific antibody recognizing a first antigen and a second antigen.

### Claim 74 (depends on 73)

The antibody of claim 73, wherein the first antigen is MS4A4A and the second antigen is:
(a) an antigen facilitating transport across the blood-brain-barrier;
(b) an antigen facilitating transport across the blood-brain-barrier selected from the group consisting of transferrin receptor (TR), insulin receptor (HIR), insulin-like growth factor receptor (IGFR), low-density lipoprotein receptor related proteins 1 and 2 (LPR-1 and 2), diphtheria toxin receptor, CRM197, a llama single domain antibody, TMEM 30(A), a protein transduction domain, TAT, Syn-B, penetratin, a poly-arginine peptide, an angiopeptide, and ANG1005;
(c) a disease-causing agent selected from the group consisting of disease-causing peptides or proteins or, disease-causing nucleic acids, wherein the disease-causing nucleic acids are antisense GGCCCC (G2C4) repeat-expansion RNA, the disease-causing proteins are selected from the group consisting of amyloid beta, oligomeric amyloid beta, amyloid beta plaques, amyloid precursor protein or fragments thereof, Tau, IAPP, alpha-synuclein, TDP-43, FUS protein, C9orf72 (chromosome 9 open reading frame 72), c9RAN protein, prion protein, PrPSc, huntingtin, calcitonin, superoxide dismutase, ataxin, ataxin 1, ataxin 2, ataxin 3, ataxin 7, ataxin 8, ataxin 10, Lewy body, atrial natriuretic factor, islet amyloid polypeptide, insulin, apolipoprotein AI, serum amyloid A, medin, prolactin, transthyretin, lysozyme, beta 2 microglobulin, gelsolin, keratoepithelin, cystatin, immunoglobulin light chain AL, S-IBM protein, Repeat-associated non-ATG (RAN) translation products, DiPeptide repeat (DPR) peptides, glycine-alanine (GA) repeat peptides, glycine-proline (GP) repeat peptides, glycine -arginine (GR) repeat peptides, proline-alanine (PA) repeat peptides, ubiquitin, and proline-arginine (PR) repeat peptides;
(d) ligands and/or proteins expressed on immune cells, wherein the ligands and/or proteins selected from the group consisting of CD40, OX40, ICOS, CD28, CD137/4-1BB, CD27, GITR, PD-L1, CTLA-4, PD-L2, PD-1, B7-H3, B7-H4, HVEM, BTLA, KIR, GALS, TIM3, A2AR, LAG-3, and phosphatidylserine; or
(e) a protein, lipid, polysaccharide, or glycolipid expressed on one or more tumor cells.

### Claim 75 (depends on 1)

An isolated nucleic acid comprising a nucleic acid sequence encoding the antibody of claim 1.

### Claim 76

(canceled)

### Claim 77 (depends on 75)

An isolated host cell comprising the nucleic acid of claim 75.

### Claim 78 (depends on 77)

A method of producing an antibody that binds to human MS4A4A, comprising culturing the cell of claim 77 so that the antibody is produced.

### Claim 79

(canceled)

### Claim 80 (depends on 1)

A pharmaceutical composition comprising the antibody of claim 1 and a pharmaceutically acceptable carrier.

### Claim 81 (depends on 1)

A method of preventing, reducing risk, or treating an individual having a disease, disorder, or injury selected from the group consisting of Alzheimer's disease, late onset Alzheimer's disease, and cognitive impairment, the method comprising administering to an individual in need thereof a therapeutically effective amount of the antibody of claim 1.

### Claim 82 (depends on 1)

A method of preventing, reducing risk, or treating an individual having a disease, disorder, condition, or injury caused by or associated with over expression or increased activity of MS4A4A, the method comprising administering to an individual in need thereof a therapeutically effective amount of the antibody of claim 1.

### Claim 83 (depends on 1)

A method of preventing, reducing risk, or treating an individual having a CSF1R-deficient disease or disorder, the method comprising administering to an individual in need thereof a therapeutically effective amount of the antibody of claim 1.

### Claim at position 43

84-85. (canceled)
